Please note: Busing from hotels to McCormick Place begins at at 6:30. Coffee/tea and a continental breakfast will be available

7:00 am - 7:45 am

Satellite A: Braveheart Bio
Advanced in HCM Treatment: Emerging Data and the Evolving Therapeutic Landscape
Caroline Coats, MD, University of Glasgow
The management of HCM remains challenging despite significant advances in the evolving treatment landscape. This session will highlight considerations in HCM management, review recent developments, and discuss emerging clinical data.

Satellite B: Bristol Myers Squibb

Room S405a

Room S405b

8:00 am - 9:30 am

Session 1 - The Latest in HCM Therapy
1. Apply current evidence and guideline-based strategies to select first-line and individualized therapies for patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
2. Evaluate current and emerging evidence for cardiac myosin inhibitors in special HCM populations, including pediatric patients and individuals with non-obstructive HCM.
3.  Describe the therapeutic pipeline for HCM, including next-generation cardiac myosin inhibitors, sarcomere modulators, and novel metabolic or disease-modifying approaches such as SGLT-based therapies.

Room S406a

8:35 am - 8:50 am

Update on Therapies for Non-Obstructive HCM

Steve Ommen, Mayo Clinic

8:50 am - 9:05 am

What's Coming

Sara Saberi, University of Michigan

9:05 am - 9:30 am

Making Choices: How to Treat Symptomatic Obstructive HCM (panel discussion)

Eric Smith, University of Michigan; Matt Martinez, Mayo Clinic; Michele Michels, Erasmus University; Daniel Swistel, NYU Langone

9:45 am - 10:45 am

Session 2 - Oral Abstracts

Room S406a

HRS/BHB-1893, a Next-Generation Cardiac Myosin Inhibitor, Improves Indices of Diastolic Function in Non-Obstructive Hypertrophic Cardiomyopathy: Evidence from in vitro Studies and Patients

Hematopoietic Loss of the Y Chromosome is
Associated with Worse Prognosis and Greater Myocardial Fibrosis in Male Patients with Hypertrophic Cardiomyopathy

Interplay Between Body Mass Index and Patient-Reported Health Status in Early-Stage Hypertrophic Cardiomyopathy

Single-Dose AAV9-051 MYBPC3 Gene Therapy with Long-Term Assessment in Hypertrophic Cardiomyopathy

Carlos del Rio

Kenneth Walsh, University of Virginia

John Ostrominski, Brigham and Women's Hospital

Yang Tao

10:45 am - 11:15 am

The Eugene Braunwald, MD, Lecture

Scott Solomon, Professor of Medicine, The Edward D. Frohich Distinguished Chair at Harvard University / Brigham and Women's Hospital

11:15 am - 12:45 pm

LUNCH. A box lunch will be provided to attendees prior to the start of the Satellite Sessions

S406b

11:45 am - 12:45 pm

Satellite C: Pfizer
When the Walls Thicken: Distinguishing ATTR-CM from Hypertrophic Cardiomyopathy
Ahmad Masri, Oregon Health and Science University; Farroq Sheikh,  MedStar Health
This session offers heart failure specialists a closer look at recognizing key features of ATTR-CM to differentiate it from HCM. Featuring expert perspectives and a patient case study, attendees will learn about a current diagnostic algorithm — including non-invasive nuclear imaging and genetic testing — as well as an approved therapy for ATTR-CM. 

Satellite D: Cytokinetcs
Clinical Conversations: Real Patient Cases, Measurable Improvements in oHCM
Mariko Harper, Virgina Mason Franciscan Health; Colby Salerno, Baystate Health
Join two cardiology experts as they walk through real-world patient cases of obstructive hypertrophic cardiomyopathy (oHCM) from their own practices. They will outline their treatment approach, including how to monitor disease progression and adjust treatment plans based on individual patient needs, as well as the functional limitations their patients have experienced because of oHCM symptoms. This candid conversation about patient management will include practical tips and key insights.

S405a

S405b

1:00 pm -2:15 pm

Session 3 - Cool New Gadgets and Interventions

1. Compare implantable cardioverter-defibrillator options for primary and secondary prevention of sudden death in patients with HCM and identify patient factors that guide device selection.
2. Evaluate contemporary strategies for atrial fibrillation ablation, including timing, repeat procedures, energy source selection, and when to stop pursuing ablation.
3. Describe emerging catheter-based and surgical approaches to septal reduction therapy.

S406a

1:00 pm - 1:15 pm

ICDs: When to Choose EV-ICD vs. sICD vs. TV-ICD

Sunny Kapur, Harvard University / Brigham and Women's Hospital

1:15 pm - 1:30 pm

AF Ablation: When, How Many, What Energy, When to Call it Quits

Bradley Knight, Northwestern Memorial Hospital

1:30 pm - 1:45 pm

New Approaches to Catheter-Based SRT

Jaffar Khan, National Institutes of Health

1:45 pm - 2:00 pm

New Approaches to Surgical Myectomy

Nick Smedira, Cleveland Clinic

2:00 pm - 2:15 pm

Panel Discussion

All Session 3 presenters and moderators

2:15 pm - 3:15 pm

Session 4 - Late Breaking Oral Abstracts

S406a

3:30 pm - 4:45 pm

Session 5 - Living Well with HCMS, Now and Into the Future

1. Explain how genetic information can improve understanding, risk assessment, and prevention strategies in hypertrophic cardiomyopathy.
   Describe emerging approaches to defining and characterizing hypertrophy, including distinctions between sarcomeric HCM and other contributors to increased wall thickness.
2. Evaluate the impact of obesity, cardiometabolic stress, and exercise on HCM outcomes and patient-centered disease management.

S406a

3:30 pm - 3:45 pm

How Can Genetic Information Help us Understand and Prevent Disease?

Adam Helms, University of Michgan

3:45 pm - 4:00 pm

Redefining HCM: New Approaches to Characterizing Hypertrophy

Charlotte Manisty, University College London

4:00 pm - 4:15 pm

Beyond the Sarcomere: The Impact of Obesity and Cardiometabolic Stress

John Ostrominsky, Harvard University/ Brigham and Women's Hospital

4:15 pm - 4:30 pm

Exercise in HCM

Ben Levine, Texas Health Resources / UT Southwestern Medical Center 

4:30 pm - 4:45 pm

Panel Discussion

All Session 5 speakers and moderators

4:45 pm - 5:30 pm

SPECIAL SATELLITE EVENT:
HCM 401: CMI Troubleshooting in the Real World

S406a

A review and discussion of advanced case studies
led by a multi-disciplinary panel operating CMI Clinics. Cardiac myosin inhibitors (CMIs) have introduced a significant advancement in the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, as clinical experience with these therapies expands, clinicians are encountering practical challenges that are not always fully addressed by clinical trials, prescribing information, or traditional educational programs.

Alex de Feria, MD, Penn Medicine; Matt Prizand, NP,  Brigham and Women's Hospital; Amy Marzolf, NP, Penn Medicine; Rachel Lavelle, PharmD, University of Chicago; Andrew Willeford, PharmD, UC San Diego; Fiona Halloran, PA-C, Children's Hospital of Philadelphia.

5:30 pm -6:30 pm

Poster Reception
This interactive session with poster presenters, speakers and GPM members offers a relaxed setting to explore research posters, exchange ideas, spark meaningful discussions, and foster new professional relationships. It's an excellent opportunity to gain insights, share feedback, and expand your network within the field.

S406b